Similar Search Results

Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain

Hidalgo-Vega, Álvaro; Ramos-Goñi, Juan; Villoro, Renata - In: The European Journal of Health Economics 15 (2014) 9, pp. 917-925

Ranolazine is a highly efficient add-on therapy for the symptomatic treatment of chronic angina pectoris in patients who are inadequately controlled by, or intolerant to, first-line antianginal therapies in Spain. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2014

Persistent link: https://www.econbiz.de/10011151208

Terminal patients in Belgian nursing homes: a cost analysis

Simoens, Steven; Kutten, Betty; Keirse, Emmanuel; … - In: The European Journal of Health Economics 14 (2013) 3, pp. 407-413

Policy makers and health care payers are concerned about the costs of treating terminal patients. This study was done … to measure the costs of treating terminal patients during the final month of life in a sample of Belgian nursing homes … from the health care payer perspective. Also, this study compares the costs of palliative care with those of usual care …

Persistent link: https://www.econbiz.de/10010993853

TIPP and Lichtenstein modalities for inguinal hernia repair: a cost minimisation analysis alongside a randomised trial

Koning, G.; Adang, E.; Stalmeier, P.; Keus, F.; Vriens, P. - In: The European Journal of Health Economics 14 (2013) 6, pp. 1027-1034

cost minimisation. For the hospital perspective no significant differences in costs were found (mean difference: €−13, 95 … costs favouring the TIPP modality (mean saving: €1,472, 95 % CI €463–€2,714) were found. The results show that TIPP is a …

Persistent link: https://www.econbiz.de/10010993871

Treatment costs of attention deficit hyperactivity disorder in Germany

Braun, Sebastian; Zeidler, Jan; Linder, Roland; Engel, … - In: The European Journal of Health Economics 14 (2013) 6, pp. 939-945

ADHD costs are relevant from health insurance perspective. The expenses for occupational therapy constitute the cost …

Persistent link: https://www.econbiz.de/10010993941

Direct costs of Alzheimer’s disease in Germany

Kiencke, Peter; Daniel, Dietmar; Grimm, Christine; … - In: The European Journal of Health Economics 12 (2011) 6, pp. 533-539

Persistent link: https://www.econbiz.de/10010539838

Costs and quality of life of multiple sclerosis in Germany

Kobelt, Gisela; Berg, Jenny; Lindgren, Peter; Elias, W.; … - In: The European Journal of Health Economics 7 (2006) 2, pp. 34-44

Persistent link: https://www.econbiz.de/10009404150

Costs and consequences of botulinum toxin type A use

Ruiz, Francis; Guest, Julian; Lehmann, Almut; Davie, Alison - In: The European Journal of Health Economics 5 (2004) 3, pp. 227-235

Persistent link: https://www.econbiz.de/10009404176

Comparison of general practitioner records and patient self-report questionnaires for estimation of costs

Mistry, Hema; Buxton, Martin; Longworth, Louise; … - In: The European Journal of Health Economics 6 (2005) 3, pp. 261-266

Persistent link: https://www.econbiz.de/10009404190

Costs and quality of life of multiple sclerosis in Spain

Kobelt, Gisela; Berg, J.; Lindgren, P.; Izquierdo, G.; … - In: The European Journal of Health Economics 7 (2006) 2, pp. 65-74

Persistent link: https://www.econbiz.de/10009404198

Costs and quality of life for patients with multiple sclerosis in Belgium

Kobelt, Gisela - In: The European Journal of Health Economics 7 (2006) 2, pp. 24-33

Persistent link: https://www.econbiz.de/10009404207